[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"menopause-surgical\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:menopause-surgical":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,57,97],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":35,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":46,"lastUpdatePostDateStruct":47,"startDateStruct":50,"completionDateStruct":52,"leadSponsor":54,"locationsCount":4},"100638708","a-retrospective-and-prospective-clinical-registry-for-data-collection-of-perimenopausal-menopausal-and-premature-ovarian-insufficiency-women-100638708",false,"NCT07606326","A Retrospective and Prospective Clinical Registry for Data Collection of Perimenopausal, Menopausal and Premature Ovarian Insufficiency Women","Inclusion Criteria:\n\n* 1\\. Age: women aged 18-60 years at the time of enrollment and in follow up, up to 65 years old\n* 2\\. Women in Perimenopause, defined as the transitional period preceding the final menstrual period, characterized by changes in menstrual cycle regularity and\u002For the onset of menopausal symptoms. Women experience variable cycle length, skipped cycles, or amenorrhea of less than 12 months' duration, often accompanied by vasomotor symptoms, sleep disturbances, and other menopause-related complaints.\n* 3\\. Women in Menopause, defined as the permanent cessation of menstruation resulting from loss of ovarian follicular activity and is diagnosed retrospectively after 12 consecutive months of amenorrhea in the absence of other pathological or physiological causes. Women may present with persistent menopausal symptoms and\u002For long-term consequences of estrogen deficiency, including changes in bone, cardiovascular, metabolic, and genitourinary health.\n\nlt includes women in early Menopause, defined as menopause occurring before the age of 45 years, but after 40 years, in the absence of surgical or iatrogenic causes.\n\n* 4\\. Women in Premature Ovarian lnsufficiency (POI), defined as impaired ovarian function occurring before the age of 40 years, characterized by oligo- or amenorrhea, elevated gonadotropin levels, and hypoestrogenism.\n* 5\\. Women with iatrogenic menopause, caused by:\n* Bilateral oophorectomy\n* Chemotherapy or radiotherapy-induced ovarian failure\n* Other pharmacological treatments resulting in ovarian insuftficiency\n* 6\\. Women evaluated at the specialized Menopause Clinic or the Multidisciplinary Endocrinology\u002FMetabolic Disorders clinic.\n* 7\\. Data availability: for retrospective participants, sufficient medical records must be available; tor prospective participants, patients must be willing to participate in the registry and provide informed consent.\n* 8\\. All women are eligible regardless of concomitant diseases, to reflect real-world clinical practice.\n\nExclusion Criteria:\n\n* 1\\. Women unable to provide informed consent due to cognitive impairment or severe psychiatric conditions.\n* 2\\. Women already participating in interventional clinical trials affecting menopausal or metabolic management in a way that could bias observational data.\n* 3\\. Women with incomplete medical records for retrospective data collection or those refusing informed consent for prospective enrollment.","FEMALE","18 Years","65 Years",{"count":19,"type":20},5000,"ESTIMATED","20 Years","OBSERVATIONAL","This study is designed as on observational, retrospective, and prospective clinical registry aimed at collecting comprehensive real-world data on women in perimenopause, menopause, and with premature ovarian insufficiency (POI) attending a specialized Menopause Clinic and a Multidisciplinary Outpatient Clinic dedicated to Endocrinology and Metabolic Disorders.\n\nThe registry comprises both retrospective data, extracted from the medical records of eligible patients evaluated from January 2000 onward, and prospective data, which will be continuously collected for all newly referred patients up to 2040. This combined design allows the longitudinal observation of clinical characteristics, management strategies, and health outcomes across different stages of the menopausal transition and premature ovarian insufficiency within routine clinical practice.\n\nClinical management and therapeutic strategies, including hormone replacement therapy and non-hormonal interventions, will be documented. Laboratory data, as well as imaging data routinely used in clinical practice, will be recorded when available.\n\nEnrolled patients will undergo a personalized follow-up schedule based on clinical findings and the conclusions of each visit, in accordance with standard clinical practice. Follow-up visits may be scheduled annually for routine monitoring or at shorter intervals (semi-annual or quarterly) in the presence of conditions requiring closer clinical surveillance.\n\nThe registry is intended to reflect real-world clinical practice and to support the descriptive evaluation of patterns of care, symptom burden, and longitudinal clinical outcomes in women undergoing the menopausal transition or affected by premature ovarian insufficiency. The collected data will provide a structured platform for epidemiological analyses and hypothesis-generating observational research aimed at improving the understanding and management of menopausal health and associated endocrine and metabolic conditions.",[25,26,27,28,29,30,31,32,33,34],"Menopause","Menopausal Hormone Therapy","Menopause Surgical","Menopause Related Conditions","Menopausal Complaints","Menopausal Osteoporosis","Menopause-related Hot Flashes","Menopausal and Perimenopausal Disorder, Unspecified","Menopausal and Postmenopausal Women","Premature Ovarian Failure (POF)",[36,37,38,39,40,41,42,43,44],"menopause","perimenopause","premature ovarian failure","hormonal replacement teraphy","osteoporosis","genitourinary syndrome of menopause","hot flashes","menopausal discomfort","menopausal symptoms","NOT_YET_RECRUITING","2026-05-19",{"date":48,"type":49},"2026-05-26","ACTUAL",{"date":51,"type":20},"2026-06",{"date":53,"type":20},"2040-12",{"name":55,"class":56},"IRCCS San Raffaele","OTHER",{"id":58,"slug":59,"hasResults":11,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":11,"sex":15,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":69,"conditions":70,"keywords":71,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":96},"100624190","hormonal-regulation-of-cardiometabolic-health-study-100624190","NCT07406412","Hormonal Regulation of Cardiometabolic Health Study","HoCa - A Multidimensional Study on Menopausal Hormonal Change, Cardiometabolic Health and Embodied Experience","HoCa","Inclusion Criteria:\n\n* Age 35-50 years\n* Pre- or perimenopausal status (defined as self-reported menstrual bleedings and\u002For follicle-stimulating hormone ≤25 IU\u002FL)\n* One or two functional ovaries\n* Planning to undergo bilateral oophorectomy or salpingo-oophorectomy (BSO) or unilateral oophorectomy or salpingo-oophorectomy (SO) if the other ovary has been previously removed, for non-malignant reasons\n\nExclusion Criteria:\n\n* Oophorectomy due to ovarian cancer or other malignant conditions\n* Current systemic estrogen-containing medication\n\nThe following exclusion criteria apply only to participation in physiological assessments (not questionnaires or interviews):\n\n* Severe heart or liver disease\n* Mobility limitations that prevent participation in physical exercise tests\n\nThe following factors do not lead to exclusion but will be recorded and considered in analyses:\n\n* Use of medications such as weight reduction drugs, lipid-lowering agents, or antihypertensives\n* Concomitant hysterectomy or other surgeries performed with oophorectomy\n* Use of local vaginal oestrogen therapy\n* Initiation of systemic hormone replacement therapy (HRT) after the 1-2-month post-surgery assessments (allowed according to clinical need; not part of the study protocol)","35 Years","50 Years",{"count":68,"type":20},120,"The goal of this observational study is to understand how the loss of ovarian function after oophorectomy affects the health and well being of women aged 35-50.\n\nThe study focuses on four areas:\n\n1. Quality of life and embodied experience,\n2. Cardiometabolic health,\n3. Central nervous system function, and\n4. Adipose tissue health and cellular function.\n\nOur primary goal is to understand the effects of oophorectomy on women's health in focus areas 1 to 3. To do this, we will compare women's health before surgery with follow up assessments at 1-2 months and 12 months after surgery. Some participants may start hormone replacement therapy (HRT) during follow up as part of their routine care; this is outside the study protocol. As an exploratory aim, we will examine whether 12 month outcomes-or the change from baseline to 12 months-differ between participants who begin HRT and those who do not.\n\nFocus area 4 provides an opportunity to explore how molecular and cellular mechanisms in adipose tissue respond to the loss of ovarian hormones. These analyses are exploratory and intended to offer mechanistic insight rather than clinical endpoints.\n\nParticipants will:\n\n* undergo bilateral (or unilateral, if only one ovary remains) oophorectomy as part of their clinical treatment,\n* complete questionnaires and physiological measurements at three time points,\n* a subgroup will participate in qualitative interviews about their lived experience of surgical menopause,\n* and a subgroup will volunteer adipose tissue samples collected during surgery.",[27],[72,25,73,74,75,76,77,78,79,80,81,82,83,84,85],"Oophorectomy","Estrogen Deficiency","Cardiometabolic Health","Quality of Life","Body Composition","Physical performance","Neurophysiology","Prospective observational study","Embodied experience","Health behavior","Adipose Tissue","Fat Oxidation","Vascular function","Menopause symptoms","RECRUITING","2026-05-05",{"date":89,"type":49},"2026-05-06",{"date":91,"type":49},"2026-02-13",{"date":93,"type":20},"2028-12-15",{"name":95,"class":56},"University of Jyvaskyla",7,{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":103,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":15,"minAge":105,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":108,"phases":109,"briefSummary":111,"conditions":112,"keywords":114,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":128},"100464708","acupuncture-withwithout-self-acupressure-for-post-oophorectomy-hot-flashes-in-brca-carriers-100464708","NCT05331209","Acupuncture With\u002FWithout Self-acupressure for Post-oophorectomy Hot Flashes in BRCA Carriers","Acupuncture With or Without Self-acupressure for Hot Flashes in Post-oophorectomy Patients With BRCA Mutations: A Prospective, Randomized Controlled Trial","BRCA","Inclusion Criteria:\n\n* Female carriers of the BRCA 1 and 2 genes\n* age ≥ 25 years\n* after risk-reducing salpingo-oophorectomy\n* reporting ≥ 5 hot flashes per day\n\nExclusion Criteria:\n\n* Patients not fulfilling the study inclusion criteria will be excluded from participation","25 Years",{"count":107,"type":20},200,"INTERVENTIONAL",[110],"NA","Risk-reducing surgery with salpingo-oophorectomy (RRSO) is the standard recommended treatment for all female carriers of BRCA genes 1 and 2. The post-surgical menopause induced is invariably accompanied by hot flashes and other symptoms, which can severely impair quality of life and function. Hormone-replacement therapy (HRT) is the standard conventional treatment for these symptoms, though these drugs do not always provide adequate relief and many patients either cannot receive them due to a diagnosis of breast cancer or hypercoagulable state; or are unwilling to take them due to their concern about the associated increased risk for developing hormone-induced breast cancer.\n\nAcupuncture and acupressure have been researched extensively and shown to be both safe and effective in reducing hot flashes in post-menopausal patients and in those with breast cancer receiving anti-hormonal drugs.\n\nThe present study will examine the effectiveness of acupuncture, with\u002Fwithout self-acupressure, on 200 post- RRSO patients who suffer from at least 5 hot flashes per day, including those treated with HRT. All participants will receive 8 weekly treatments with acupuncture, and then randomly assigned to receive (or not) self-administered acupressure, to be performed daily at home. The response to the study interventions will be assessed using daily Hot Flash Scores, the Menopause Specific Quality of Life (MenQoL) and Measure Yourself Concerns and Wellbeing (MYCAW) questionnaires (at baseline; at the end of the 8-week intervention; and at 16 weeks). The safety of the study treatments will be assessed throughout.",[113,27],"Hot Flashes",[115,116,42,117,118],"acupuncture","acupressure","surgical menopause","quality of life","2026-04-23",{"date":121,"type":49},"2026-04-29",{"date":123,"type":20},"2026-12-01",{"date":125,"type":20},"2028-12-31",{"name":127,"class":56},"Shaare Zedek Medical Center",1]